BioSpace News Archive

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mediterranean.

BioXcel Therapeutics, Inc. announced the formation of wholly-owned subsidiary OnkosXcel Therapeutics, Inc. to develop transformative medicines in oncology.

Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program ADI-001.

Aurinia Pharmaceuticals Inc. today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs.

Quipt Home Medical Corp. is very pleased to announce that it has acquired Good Night Medical, LLC, a business with operations across seven U.S. states, reporting unaudited trailing 12-month annual revenues of approximately $7.5 million ‎and with anticipated Adjusted EBITDA of $1.5 million post integration.

HCW Biologics Inc. announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology taking place in Boston, Massachusetts on April 18-20, 2022.

NextCure, Inc. announced the publication of a paper titled “Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication” in the Journal of Clinical Investigation.

KemPharm, Inc. today announced that the first subject has been dosed in a Phase 1 clinical trial designed to assess the relative cardiovascular safety of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate).

Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson.

Actinium Pharmaceuticals, Inc. today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held April 23 – 26, 2022 virtually and in Salt Lake City, Utah.